



ASX ANNOUNCEMENT

20 August 2020

## New Contract with Bayer AG for the AVANTI Heart Trial

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce that global pharmaceutical company Bayer AG and CardieX subsidiary ATCOR have this week entered into a new Amended Agreement for both the lease of ATCOR devices and the provision of expanded data management services for Bayer's "AVANTI" trial.

Bayer (OTCMKTS: BAYZF: \$USD17b) originally contracted ATCOR to provide clinical trial lab and data management services and devices for the AVANTI trial through to October, 2020 with a contract value of \$USD1.26M. The total value of this contract and ongoing trial has this week been increased an additional \$USD420K to \$USD1.68M under a new Amended Agreement.

In addition, the term of the contract has been extended through to June, 2021 with the additional AVANTI Amended Contract revenue to be accrued by the Company in the current FY 2021.

The AVANTI trial is one of two (2) significant ongoing trials that ATCOR currently has under contract with Bayer – the other being the CONCORD trial. Previous announcements this year in regards to other trial contract amendments and increases referred to the Bayer CONCORD trial (refer ASX release 26/3/20) as well as a prior amendment to the Bayer AVANTI trial also announced earlier this year (refer ASX release 13/3/20).

### ***Summary of terms of the new incremental Amended Contract for the Bayer AVANTI trial:***

Terms of the Bayer AVANTI trial prior to this week's amendment:

- Approximately 70 clinical trial sites across 9 European countries.
- ATCOR XCEL Systems leased through October 2020.
- Study being conducted in a heart failure population.
- Data management services for 2,353 unique patient visits.
- **Contract value of \$USD1.26M.**

Impact of new Amended Contract and new revenues:

- ATCOR XCEL system lease extension through June 2021.
- 185 incremental patient visits for a total of 2,538 patient visits.
- **Increase in contract value - of \$USD420K.**
- **Total contract value - \$US1.68M.**



This increase in contract value with Bayer is consistent with recent announcements by CardieX that we were expecting further amendments in respect of additional existing trials as well as new trial contracts in the immediate future – together adding significant new incremental revenue to the Company for FY 2021.

ATCOR's XCEL device is the only FDA cleared device for measuring the central aortic waveform and reporting on associated clinical data in all adult subjects. XCEL is used by clinicians, research institutions, and pharmaceutical companies in monitoring critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.

**Craig Cooper, CEO & Managing Director commented:**

*"This new contract amendment is testament to the ongoing business development success of the Company as we continue to move through this difficult economic period – and is further validation of the unique capabilities of our FDA-cleared SphygmoCor® technology that the Company is actively expanding into wearables, smart devices and other new markets".*

**Authorised for release by the full Board of Directors, and released by Jarrod White**

For more information please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com](mailto:melissa.hamilton@mcpartners.com)

**About CardieX**

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR.X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).